Organovo is a biotech company that has 3D technology enabling the company to produce various human tissues, allowing the company to target diseases and accelerate the drug development process. The company recently released positive Phase 2 results for one of its primary treatments-FXR314. These results are very encouraging and bolsters our belief in the future prospects for ONVO.
01 May 2024
ONVO: Positive Phase 2 Results Bolsters Outlook
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
ONVO: Positive Phase 2 Results Bolsters Outlook
Organovo is a biotech company that has 3D technology enabling the company to produce various human tissues, allowing the company to target diseases and accelerate the drug development process. The company recently released positive Phase 2 results for one of its primary treatments-FXR314. These results are very encouraging and bolsters our belief in the future prospects for ONVO.